CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
20. Mai 2021 03:30 ET
|
CatalYm GmbH
MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
04. Mai 2021 05:00 ET
|
CatalYm GmbH
MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief...